James W Murrough

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Biol Psychiatry 74:250-6. 2013
  2. pmc Is there anything really novel on the antidepressant horizon?
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Curr Psychiatry Rep 14:643-9. 2012
  3. pmc Ketamine as a novel antidepressant: from synapse to behavior
    J W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    Clin Pharmacol Ther 91:303-9. 2012
  4. doi request reprint Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Neurobiol Learn Mem 96:553-63. 2011
  5. doi request reprint Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression
    Marije aan het Rot
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York
    Biol Psychiatry 67:139-45. 2010
  6. ncbi request reprint Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder
    James W Murrough
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    NMR Biomed 23:643-50. 2010
  7. pmc Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Neuropsychopharmacol 13:71-82. 2010
  8. pmc Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology
    Dikoma C Shungu
    Department of Radiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    NMR Biomed 25:1073-87. 2012
  9. pmc Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence
    Alexander Neumeister
    Molecular Imaging Program, Department of Psychiatry and Radiology, New York University School of Medicine, New York, New York 10016, USA
    Alcohol Clin Exp Res 36:2104-9. 2012
  10. pmc Reduced amygdala serotonin transporter binding in posttraumatic stress disorder
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Biol Psychiatry 70:1033-8. 2011

Collaborators

Detail Information

Publications20

  1. pmc Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Biol Psychiatry 74:250-6. 2013
    ..In the current report, we examined the pattern and durability of antidepressant effects of repeated ketamine infusions in a larger sample, inclusive of the original...
  2. pmc Is there anything really novel on the antidepressant horizon?
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Curr Psychiatry Rep 14:643-9. 2012
    ..We review in detail findings regarding the antidepressant effects of the glutamate N-methyl-d-aspartate receptor antagonist ketamine in order to highlight the promise of novel agents as future treatments for major depression...
  3. pmc Ketamine as a novel antidepressant: from synapse to behavior
    J W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    Clin Pharmacol Ther 91:303-9. 2012
    ....
  4. doi request reprint Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Neurobiol Learn Mem 96:553-63. 2011
    ..Finally, we highlight potential new pharmacological and non-pharmacological therapeutic strategies for MDD based on an evolving mechanistic understanding of the disorder...
  5. doi request reprint Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression
    Marije aan het Rot
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York
    Biol Psychiatry 67:139-45. 2010
    ....
  6. ncbi request reprint Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder
    James W Murrough
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    NMR Biomed 23:643-50. 2010
    ..Future (1)H MRS studies with larger sample sizes and well-characterized populations will be necessary to further clarify the sensitivity and specificity of neurometabolic abnormalities in CFS and MDD...
  7. pmc Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Neuropsychopharmacol 13:71-82. 2010
    ..Riluzole did not prevent relapse in the first month following ketamine. Further investigation of relapse prevention strategies post-ketamine is necessary...
  8. pmc Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology
    Dikoma C Shungu
    Department of Radiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    NMR Biomed 25:1073-87. 2012
    ..Collectively, the results of this third independent study support a pathophysiological model of CFS in which increased oxidative stress may play a key role in CFS etiopathophysiology...
  9. pmc Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence
    Alexander Neumeister
    Molecular Imaging Program, Department of Psychiatry and Radiology, New York University School of Medicine, New York, New York 10016, USA
    Alcohol Clin Exp Res 36:2104-9. 2012
    ..This is an important gap in the literature, because recent therapeutic developments suggest that these receptors could be targeted for the treatment for AD...
  10. pmc Reduced amygdala serotonin transporter binding in posttraumatic stress disorder
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Biol Psychiatry 70:1033-8. 2011
    ....
  11. pmc The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding
    James W Murrough
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, USA
    Arch Gen Psychiatry 68:892-900. 2011
    ..However, the specific role of the serotonin type 1B receptor has not been studied in patients with PTSD...
  12. ncbi request reprint Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial
    Adriana Feder
    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
    JAMA Psychiatry 71:681-8. 2014
    ..If replicated, these findings may lead to novel approaches to the pharmacologic treatment of patients with this disabling condition. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00749203. ..
  13. pmc A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 21:221-9. 2011
    ..The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD. (ClinicalTrials.gov Identifier: NCT 00211861, NCT 00383786)...
  14. ncbi request reprint In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder
    Kyle A B Lapidus
    Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA Electronic address
    Neurosci Lett 569:74-9. 2014
    ..These preliminary findings are potentially consistent with a pathophysiological role for GSH and oxidative stress in anhedonia and MDD. Larger studies in anhedonic depressed patients are indicated. ..
  15. pmc Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder
    Rebecca B Price
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Biol Psychiatry 65:792-800. 2009
    ....
  16. ncbi request reprint Attention bias variability and symptoms of posttraumatic stress disorder
    Brian M Iacoviello
    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA
    J Trauma Stress 27:232-9. 2014
    ..Attention-bias variability could be a useful marker for attentional impairment related to threat cues associated with mood and anxiety symptoms after trauma exposure...
  17. pmc Neurobiology of resilience
    Scott J Russo
    Department of Neuroscience, Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York, USA
    Nat Neurosci 15:1475-84. 2012
    ..The therapeutic implications of these findings are important and can pave the way for an innovative approach to drug development for a range of stress-related syndromes...
  18. pmc Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder
    James W Murrough
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Psychopharmacology (Berl) 213:547-53. 2011
    ..In particular, 5-HT(1B) heteroreceptors located within the striatum have been shown to play an essential role in antidepressant action...
  19. doi request reprint A functional magnetic resonance imaging study of deliberate emotion regulation in resilience and posttraumatic stress disorder
    Antonia S New
    Mental Health Care Center, James J Peters Veterans Affairs Medical Center, Bronx, New York, New York 10468, USA
    Biol Psychiatry 66:656-64. 2009
    ..g., trauma-exposed non-PTSD). In this project, we examined the neural mechanisms underlying differences in response to sexual violence, focusing specifically on the deliberate modification of emotional responses to negative stimuli...